Lupin Invests $250 Million in New Coral Springs Manufacturing Facility to Bolster US Respiratory Drug Supply

October 13, 2025

The global generics maker’s new Florida site will produce more than 25 critical respiratory medicines, create over 200 jobs, and reinforce domestic manufacturing and drug security.

Lupin, a manufacturer of complex generics, will be constructing a new state-of-the-art pharma manufacturing facility in Coral Springs, FL. Investment on the project is expected to total approximately $250 million, which includes research & development, infrastructure, and capital expenses over five years.1

Boosting US respiratory drug production and supply chain resilience

The new site is expected to have the capability to manufacture more than 25 critical respiratory meds, such as albuterol inhalers for children with asthma and service members both at home and overseas. According to the company, the new plant offers various positives, including a boost in local manufacturing, supply chain diversification, and the strengthening of drug security. For the Broward County area, the newly announced project with open up over 200 new long-term, skilled jobs by the year 2030.

“The expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy. This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin’s headquarters and our Advanced Inhalation Research Center,” explained Christoph Funke, Lupin’s chief technical operations officer. “This investment demonstrates Lupin’s commitment to innovation, quality and supply chain reliability—and our ability to partner with Florida’s leaders to strengthen America’s medicine security by growing our capacity to produce affordable treatments for patients. We are grateful to Florida’s leadership for their partnership in making this possible.”

A key hub for US respiratory therapy manufacturing

The Coral Springs site will serve as a key hub for US production of essential respiratory treatments, strengthening supply chain resilience and expanding affordable access, from everyday pediatric care to large-scale public health emergencies. The 70,000-square-foot project spans more than five acres of newly acquired land.

“On behalf of FloridaCommerce, I’m excited to welcome Lupin’s expansion in Coral Springs and the high-impact investment it brings to our state,” said Florida Secretary of Commerce J. Alex Kelly. “Thanks to Governor DeSantis’ leadership, Florida has built a strong foundation for growth—with a strong focus on research and development, nine consecutive years as the #1 state for postsecondary education and three consecutive years as the #1 state for talent development, Florida has become #2 in the nation for both pharmaceutical and medical device manufacturing. Lupin’s investment will strengthen Florida’s position as a leader in life sciences, boost our advanced manufacturing capabilities and enhance the state’s medicine security—delivering long-term benefits to both our economy and the health of Floridians.”

Global manufacturing expansion in context

Lupin’s latest moves marks a series of manufacturing announcements that have come from players in the pharma sector, including Eli Lilly. Over the next few years, the company has financially committed over $1 billion toward bolstering its manufacturing and supply in India.2 The pharma powerhouse has been looking to expand its production efforts on a global scale via contract manufacturing, and the new hub does exactly that—creating a way to manage the company’s network throughout India while offering expanded technical capabilities.

The Big Pharma company also previously announced that it would be constructing a new $6.5 billion manufacturing facility at Generation Park in Houston, TX. This represents the second of four sites in the United States that Lilly plans to reveal this year, with the first being a $5 billion production plant in Goochland County, VA that will be considered the company's first fully integrated facility dedicated to APIs and drug product.2

These moves come during a time in which a 100% tariff on branded and patented drugs was expected to take effect Oct. 1, unless pharma companies build domestic production facilities, although there have also been reports saying the US president may not enact the triple-digit pharma tariffs after all.

References

1. Lupin Announces Plans to Build a New State-of-the Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America’s Patients and Healthcare System. Lupin. October 8, 2025. Accessed October 13, 2025. https://www.lupin.com/lupin-announces-plans-to-build-a-new-state-of-the-art-manufacturing-facility-in-coral-springs-florida/#:~:text=Investors-,Lupin%20Announces%20Plans%20to%20Build%20a%20New%20State%2Dof%2Dthe,members%20at%20home%20and%20overseas.

2. Saraceno N. Eli Lilly Invests Over $1 Billion to Strengthen Manufacturing and Supply Capabilities in India. Pharmaceutical Commerce. October 7, 2025. Accessed October 13, 2025. https://www.pharmaceuticalcommerce.com/view/eli-lilly-invests-over-1-billion-strengthen-manufacturing-supply-capabilities-india

Lupin Invests $250 Million in New Coral Springs Manufacturing Facility to Bolster US Respiratory Drug Supply

Boosting US respiratory drug production and supply chain resilience

Fast facts: Lupin's Coral Springs expansion

A key hub for US respiratory therapy manufacturing

Global manufacturing expansion in context